Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Blinatumomab Consolidation in Younger Adult BCR:ABL1–Negative B-ALL

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab consolidation in BCR:ABL1–negative B-ALL.

Adding Blinatumomab to the CALGB 10403 Regimen in B-Cell Precursor ALL in MRD-Negative Remission

September 2nd 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.

Rilzabrutinib Nets Approval in Pretreated Immune Thrombocytopenia

September 2nd 2025

Rilzabrutinib has been approved by the FDA for persistent or chronic immune thrombocytopenia after an insufficient response to prior therapy.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

EMA Grants Orphan Drug Designation to OXC-101 for Acute Myeloid Leukemia

September 1st 2025

The European Medicines Agency has granted orphan drug designation to OXC-101 for the treatment of acute myeloid leukemia.

ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites

August 29th 2025

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

Dr Vose on the Development of Epcoritamab in Relapsed/Refractory DLBCL

August 28th 2025

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Annamycin Plus Cytarabine Drive Potential OS Benefit in Acute Myeloid Leukemia

August 28th 2025

Annamycin plus cytarabine produced a potential overall survival benefit in acute myeloid leukemia.

Long-Term Outcomes Strengthen Role of Pola-R-CHP in Frontline DLBCL Management

August 28th 2025

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

European Commission Greenlights UM171 Cell Therapy for Hematologic Malignancies

August 27th 2025

UM171 cell therapy has earned European Commission approval for the treatment of patients with hematologic malignancies requiring HSCT.

Defining the Role of Blinatumomab in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the role of blinatumomab in acute lymphoblastic leukemia management.

Current First-Line Treatment Considerations in Acute Lymphoblastic Leukemia

August 25th 2025

Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss first-line treatment options for acute lymphoblastic leukemia.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

EMA Grants Orphan Drug Designation to Pegtarazimod for GVHD

August 23rd 2025

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

Health Canada Approves Glofitamab Plus Chemotherapy for R/R DLBCL

August 22nd 2025

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Evolving Treatment Strategies Reshape the Landscape of Hematologic Malignancies

August 22nd 2025

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Experts Expand on the Impact of Removing REMS Requirements for CAR T-Cell Access in Hematologic Malignancies

August 21st 2025

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

August 21st 2025

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.